Andere talen Citius Pharmaceuticals, Inc.

Aandelen

CTXR

US17322U2078

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6221 ^USD	-7,15%		+1,88%	-17,77%

21/05	Citius Pharmaceuticals, Inc. Behaalt primaire en secundaire eindpunten in Fase 3-studie met Mino-Lok Antibiotic Lock Solution	CI
14/05	Citius Pharmaceuticals, Inc. rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	29/05
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05
Citius Pharmaceuticals : CTXR Factsheet	15/05
Citius Pharmaceuticals : CTXR Corporate Presentation	15/05
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update	14/05
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14/05
Citius Pharmaceuticals to Participate In Upcoming EF Hutton and H.C. Wainwright Investor Conferences	13/05
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences	10/05
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering	30/04
Citius Pharmaceuticals Launches $15 Million Offering	26/04
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	26/04
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	04/04
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18/03
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	18/03
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	07/03
Citius Pharmaceuticals to Participate In Upcoming BIO CEO and Sidoti Investor Conferences	26/02
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Citius Pharmaceuticals, Inc.

Aandelen

CTXR

US17322U2078

Andere talen

Filters